An update from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) is now available.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of study results for its core product, sacituzumab tirumotecan (sac-TMT), at the 2025 ASCO Genitourinary Cancers Symposium. The Phase 1/2 study showed promising efficacy and safety results for patients with advanced urothelial carcinoma who had previously undergone anti-cancer therapies. The objective response rate was notable, and while some adverse effects were observed, they were generally manageable. This development positions the company favorably within the oncology sector, highlighting its innovative approach to targeting cancer cells and enhancing its market presence.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, specializing in the development of antibody drug conjugates (ADCs) for the treatment of advanced solid tumors. Its core product, sacituzumab tirumotecan (sac-TMT), targets tumors such as lung, breast, and gastric cancers, leveraging proprietary technology to deliver its therapeutic payload effectively.
YTD Price Performance: 9.06%
Average Trading Volume: 293,726
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$39.69B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.